MBRX
Moleculin Biotech, Inc.
Biotechnology
Market Cap$29M
5Y Perf.-97.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MBRX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+11.7%
MBRX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MBRX | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $29M | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-24M | $-464M |
| Total Debt | $222K | $98K |
| Cash & Equiv. | $9M | $714M |
MBRX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MBRX
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Moleculin Biotech, … (MBRX) | 100 | 2.5 | -97.5% |
| Immunovant, Inc. (IMVT) | 100 | 111.7 | +11.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBRX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBRX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MBRX
Moleculin Biotech, Inc.
The Income Pick
MBRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.22, yield 0.4%
- EPS growth 82.0%
- Lower volatility, beta 1.22, Low D/E 1.5%, current ratio 1.41x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 188.1% 10Y total return vs MBRX's -99.7%
- 3.2% margin vs MBRX's 0.5%
- -44.1% ROA vs MBRX's -112.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MBRX | -10.1% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs MBRX's 0.5% |
| Stability / Safety | MBRX | Beta 1.22 vs IMVT's 1.37 |
| Dividends | MBRX | 0.4% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | MBRX | +143.1% vs IMVT's +107.2% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs MBRX's -112.5% |
MBRX vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGMBRX
MBRXMoleculin Biotech, In…
1leads
IMVTImmunovant, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs MBRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MBRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MBRX and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$25M | -$487M |
| Net IncomeAfter-tax profit | -$24M | -$464M |
| Free Cash FlowCash after capex | -$23M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +134.5% | +19.7% |
MBRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MBRX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $29M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $21M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -0.09x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.96x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MBRX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-3 for MBRX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MBRX's 0.01x. On the Piotroski fundamental quality scale (0–9), MBRX scores 3/9 vs IMVT's 2/9, reflecting mixed financial health.
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -47.1% |
| ROA (TTM)Return on assets | -112.5% | -44.1% |
| ROICReturn on invested capital | -4.4% | — |
| ROCEReturn on capital employed | -187.1% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.01x | 0.00x |
| Net DebtTotal debt minus cash | -$9M | -$714M |
| Cash & Equiv.Liquid assets | $9M | $714M |
| Total DebtShort + long-term debt | $222,000 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $486 for MBRX. Over the past 12 months, MBRX leads with a +143.1% total return vs IMVT's +107.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs MBRX's -40.8% — a key indicator of consistent wealth creation.
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -31.5% | +10.7% |
| 1-Year ReturnPast 12 months | +143.1% | +107.2% |
| 3-Year ReturnCumulative with dividends | -79.2% | +48.4% |
| 5-Year ReturnCumulative with dividends | -95.1% | +73.9% |
| 10-Year ReturnCumulative with dividends | -99.7% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -40.8% | +14.1% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MBRX and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MBRX is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 95.3% from its 52-week high vs MBRX's 31.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.37x |
| 52-Week HighHighest price in past year | $7.98 | $30.09 |
| 52-Week LowLowest price in past year | $0.25 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +31.1% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 113K | 1.4M |
Evenly matched — MBRX and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MBRX as "Buy" and IMVT as "Buy". MBRX is the only dividend payer here at 0.35% yield — a key consideration for income-focused portfolios.
| Metric | MBRXMoleculin Biotech… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $45.50 |
| # AnalystsCovering analysts | 4 | 23 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.01 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMVT leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). MBRX leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 2 of 6 categories
Loading custom metrics...
MBRX vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MBRX or IMVT a better buy right now?
Analysts rate Moleculin Biotech, Inc.
(MBRX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MBRX or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -95. 1% for Moleculin Biotech, Inc. (MBRX). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus MBRX's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MBRX or IMVT?
By beta (market sensitivity over 5 years), Moleculin Biotech, Inc.
(MBRX) is the lower-risk stock at 1. 22β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 13% more volatile than MBRX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 1% for Moleculin Biotech, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — MBRX or IMVT?
On earnings-per-share growth, the picture is similar: Moleculin Biotech, Inc.
grew EPS 82. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MBRX or IMVT?
Moleculin Biotech, Inc.
(MBRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBRX leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — MBRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MBRX or IMVT?
In this comparison, MBRX (0.
4% yield) pays a dividend. IMVT does not pay a meaningful dividend and should not be held primarily for income.
07Is MBRX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+188. 1% 10Y return). Both have compounded well over 10 years (IMVT: +188. 1%, MBRX: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MBRX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.